Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.
How it helps
Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.
With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.
How it works
Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.
Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.
Scrip
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.
Topic Coronavirus
Scrip
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.
Topic Coronavirus
Scrip
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Topic Coronavirus
Scrip
Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.
Topic Coronavirus
Scrip
Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.
Topic Coronavirus Clinical Trials
Scrip
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Topic Coronavirus Financing Innovation
Scrip
The unveiling of US president Donald Trump’s 'Warp Speed’ plan to fast-track a coronavirus vaccine and the latest promising Phase I data from Moderna's candidate haven't seemed to swing China’s belief that it’s still leading the race.
Topic Coronavirus
Scrip
First eight volunteers produced antibodies which match or surpass those seen in patients who have recovered from COVID-19 – but big test awaits in Phase III.
Topic Coronavirus
Scrip
Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.
Topic Coronavirus Leadership Strategy
Scrip
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Scrip
A Phase III trial testing Kevzara in hospitalized COVID-19 patients will continue only with the high dose in more advanced critical patients after the low-dose was unsuccessful.
Scrip
Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.
Topic Coronavirus Sales Earnings
Scrip
The coronavirus pandemic could dull pharma M&A activity in the short-term as companies hoard cash and prioritize core activities. But experts say stress in the system could potentially push some firms to cull surplus assets or seek financial/strategic investors, amid a generally tough funding environment. Private equity investors may also find attractive investment opportunities to pursue.
Topic Coronavirus
Scrip
Small-to-medium non-profit making UK biotechs will be supported via loans and grants, but government unmoved by Tax Credits suggestion for whole sector.
Topic Coronavirus
Scrip
Gilead’s front-running antiviral to fight the coronavirus has shown rapid improvement in severe patients’ symptoms in one US study but some are not convinced.
Topic Coronavirus
Scrip
15 May 2020
Scrip
15 May 2020
Scrip
15 May 2020
Scrip
15 May 2020
Scrip
15 May 2020
Scrip
15 May 2020
Scrip
15 May 2020
Scrip
14 May 2020
Scrip
14 May 2020
Scrip
14 May 2020
Scrip
14 May 2020
Scrip
14 May 2020
Scrip
14 May 2020
Scrip
14 May 2020
Scrip
14 May 2020
New York, USA
Brenda specializes in
+39 year(s) experience
Washington DC, USA
Cathy specializes in
+39 year(s) experience
Washington DC, USA
Denise specializes in
+38 year(s) experience
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
